China’s biopharma sector ‘in prime position to challenge US leadership’
American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase
China’s biopharmaceutical sector is said to have entered an “innovation 2.0” phase as it moves to a commercialisation mindset that could see it sideline global competitors and outpace the US – despite restrictive trade policies.
According to a new report on mainland Chinese biopharmaceutical innovation by analytics company Clarivate, China has matured from a phase of rapid expansion to an “innovation 2.0” phase of quality-focused development.
“This transition represents a fundamental shift in priorities: from speed to quality, from chasing market trends to building sustainable competitive advantages, and from capital-driven growth to value-driven development,” according to the report published on December 8.
Alice Zeng, one of the authors of the report and a senior consultant at Clarivate Life Sciences and Healthcare, said China’s focus in the past decade had been on how to do research and development – not what happened after a drug was approved and launched.